David-Alexandre “DA” Gros has joined Neurocrine Biosciences (Nasdaq: NBIX) as president and chief operating officer, the American biotech group announced today.
The California-headquartered company recruited Dr Gros from Alnylam Pharmaceuticals (Nasdaq: ALNY) where he served as senior vice president and chief business officer.
"Neurocrine is very pleased to welcome Dr Gros as we move forward with our transformation into a commercial entity," said Kevin Gorman, chief executive at the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze